Synthesis and intestinal metabolism of ursodeoxycholic acid conjugate with an antiinflammatory agent, 5-aminosalicylic acid

Journal of Lipid Research

Volumn 39, Issue 8, 1998, Pages 1641-1646

  Batta, Ashok K ^a   Tint, G Stephen ^a   Xu, Guorong ^a   Shefer, Sarah ^a   Salen, Gerald ^a  

^a NONE

Author keywords

Colon; Inflammatory bowel disease; Intestinal bacteria; Ulcerative colitis; Ursodeoxycholic acid; Ursodeoxycholic acid 5 aminosalicylic acid conjugate

Indexed keywords

ANTIINFLAMMATORY AGENT; MESALAZINE; URSODEOXYCHOLIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BILE ACID SYNTHESIS; COLON FLORA; CONTROLLED STUDY; CROHN DISEASE; DRUG CONJUGATION; DRUG HYDROLYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; ULCERATIVE COLITIS;

AMIDOHYDROLASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL TRANSPORT, ACTIVE; CLOSTRIDIUM PERFRINGENS; COLONIC POLYPS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL ABSORPTION; INTESTINES; MESALAMINE; RATS; URSODEOXYCHOLIC ACID;

EID: 0031846235     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Allgayer, H. 1992. Sulfasalazine and 5-ASA compounds. Gasteroenterol. Clin. North Am. 21: 643-658.
2. Myers, S., D. N. W. Evans, J. Rhodes, B. K. Evans, B. R. Hughes, M. G. Lee, A. Richens, and D. Richards. 1987. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 28: 196-200.
3. van Hees, P. A. M., J. H. Baker, and J. H. M. vonTengeren. 1980. Effect of sulfapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: a study to determine the active moiety of sulphasalazine. Gut. 21: 632-635.
4. Biddle, W. L., N. J. Greenberger, and J. T. Swan. 1988. 5-Aminosalicylic enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology. 94: 1075-1079.
5. Jarnerot, G. 1989. Newer 5-aminosalicylic acid base drugs in chronic inflammatory bowel disease. Drugs. 37: 73-86.
6. Selby, W. S., G. D. Barr, A. Ireland, C. H. Mason, and D. P. Jewell. 1985. Olsalazine in active ulcerative colitis. Br. Med. J. 291: 1373-1375.
7. Leuschner, U., H. Fischer, W. Kurtz, S. Guldutuna, K. Hubner, A. Hellstern, M. Gatzen, and M. Leuschner. 1991. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology. 100: 203-211.
8. Salen, G., A. Colalillo, D. Verga, E. Bagan, G. S. Tint, and S. Shefer. 1980. Effect of high and low doses of ursodeoxycholic acid on gallstone dissolution in humans. Gastroenterology. 78: 1412-1418.
9. Stiehl, A., P. Czygan, B. Kommerell, H. J. Weis, and K. H. Holtermuller. 1978. Ursodeoxycholic acid versus chenodeoxycholic acid. Comparison of their effects on bile lipid composition in patients with cholesterol gallstones. Gastroenterology. 75: 1016-1020.
10. Kramer, W., G. Wess, G. Schubert, M. Bickel, F. Girbig, U. Gutjahr, S. Kowalewski, K-H. Baringhaus, A. Enhsen, H. Gilombik, S. Mullner, G. Neckermann, S. Schulz, and E. Pitzinger. 1992. Liver-specific drug targeting by coupling to bile acids. J. Biol. Chem. 267: 18598-18604.
11. Petzinger, E., L. Nickau, J. A. Horz, S. Schulz, G. Wess, A. Enhsen, E. Falk, K-H. Baringhaus, H. Glombik, A. Hoffmann, S. Mullner, G. Neckermann, and W. Kramer. 1995. Hepatobiliary transport of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors conjugated with bile acids. Hepatology. 22: 1801-1811.
12. Heuman, D. M., and R. Bajaj. 1994. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology. 106: 1333-1341.
13. Heuman, D. M., A. S. Mills, J. McCall, P. B. Hylemon, W. M. Pandak, and Z. R. Vlahcevic. 1991. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo study in the rat. Gastroenterology. 100: 203-211.
14. Earnest, D. L., H. Holubec, R. K. Wali, C. S. Jolley, M. Bissonnette, A. K. Bhattacharyya, H. Roy, S. Khare, and T. A. Brasitus. 1994. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 54: 5071-5074.
15. Batta, A.K., R. Arora, G. Salen, G. S. Tint, D. Eskreis, and S. Katz. 1989. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. J. Lipid Res. 30: 1953-1962.
16. Batta, A. K., G. Salen, S. Shefer, G. S. Tint, and B. Dayal. 1982. The effect of tauroursodeoxycholic acid and taurine supplementation on biliary bile acids composition. Hepatology. 2: 811-816.
17. Batta, A. K., G. Salen, and S. Shefer. 1989. Characterization of sarcosylsarcoursodeoxycholic acid formed during the synthesis of sarcoursodeoxycholic acid. J. Lipid Res.. 30: 771-774.
18. Batta, A. K., G. Salen, and S. Shefer. 1984. Substrate specificity of cholylglycine hydrolase for the hydrolysis of bile acid conjugates. J. Biol. Chem. 254: 15035-15039.
19. Tserng, K-Y., D. L. Hachey, and P. D. Klein. 1977. An improved procedure for the synthesis of glycine and taurine conjugated bile acids. J. Lipid Res. 18: 404-407.
20. Norman, A. 1955. Preparation of conjugated bile acids using mixed carboxylic acid anhydrides. Bile acids and steroids. Ark. Kemi. 8: 331-342.
21. 1H FT-NMR Spectra. Aldrich Chemical Co., Milwaukee, WI, 1st Edition. 2: 1121c.
22. Waterhous, D. V., S. Barnes, and D. D. Muccio. 1985. Nuclear magnetic resonance spectroscopy of bile acids. Development of two-dimensional NMR methods for the elucidation of proton resonance assignments for five common hydroxylated bile acids, and their parent bile acid, 5β-cholanoic acid. J. Lipid Res. 26: 1068-1078.
23. Iida, T., T. Tamura, T. Matsumoto, and F. C. Chang. 1983. Carbon-13 NMR spectra of hydroxylated bile acid stereoisomers. Org. Magn. Reson. 21: 305-309.
24. Nair, P. P., M. Gordon, and J. J. Rebach. 1967. The enzymatic cleavage of the carbon-nitrogen bond in 3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholan-24-oylglycine. J. Biol. Chem. 242: 7-11.
25. Tint, G. S., G. Salen, A. Colalillo, D. Graber, D. Verga, J. Speck, and S. Shefer. 1982. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann. Intern. Med. 97: 351-356.
26. Salen, G., A. K. Batta, and G. S. Tint. 1997. Bile acid abnormalities in biliary tract diseases. Curr. Hepatol. 17: 275-298.
27. II, and -ζ. Cancer Res. 55: 5257-5264.
28. Invernizzi, P., A. L. Salzman, and K. D. R. Setchell. 1995. Ursodeoxycholic acid inhibits induction of the human intestinal epithelial nitric oxide synthase. Hepatology. 22: 361A.
29. Olsson, R., A. Danielsson, G. Jarnerot, E. Lindstrom, L. Loof, P. Rolny, B-O. Ryden, C. Tysk, and S. Wallerstedt. 1991. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 100: 1319-1323.
30. O'Brien, C. B., J. R. Senior, R. Arora-Mirchandani, A. K. Batta, and G. Salen. 1991. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology. 14: 838-847.